Please assess the completion status of the following clinical trial:

Trial Title: Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IgE-mediated peanut allergy, confirmed at double-blind placebo-controlled food challenge~* Tolerant to at least 1/4 boiled peanut (boiled for 4 hours) at open food challenge.~* Informed consent of parent/legal guardian and patient assent~Exclusion Criteria:~* Allergic to 1/4 boiled peanut at PCFC~* Tolerates ≥1.4 g roasted peanut protein at entry PCFC~* Unstable asthma~* Unwilling or unable to fulfil study requirements~* Undergoing other forms of immunotherapy (e.g. SCIT or SLIT to aeroallergens)~* Previous admission to ICU for management of allergic reaction to peanut~* Clinically significant chronic illness (other than asthma, rhinitis or eczema).~* Undergoing subcutaneous or sublingual immunotherapy and within the first year of therapy, for respiratory allergy.~* Subjects receiving anti-IgE therapy, oral immunosupressants, beta-blocker or ACE inhibitor therapy.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Desensitisation to peanut (Type: EXPERIMENTAL): Desensitisation using boiled peanut
- Control (Type: EXPERIMENTAL): Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).